First-ever made-in-China oncology med wins approval

Sep 05, 2018

The “Made in China” label may be ubiquitous on a wide array of products found in the U.S., but it hasn’t been stamped on many cancer drugs — at least, not until now.

This week, the National Medical Products Administration of China approved fruquintinib, a colorectal cancer treatment that was developed as a collaboration between Hutchinson China MediTech (Chi-Med) and Eli Lilly. The medication is the first-ever oncology drug that was discovered and developed in China to get a regulatory nod after a randomized clinical trial.

It is also slated to be introduced in the U.S. and EU after its rolled out in China — which is the reverse direction of the typical global regulatory path of new drugs. 

The approval marks a big win for China, which has been hoping to bolster its presence in the global biopharmaceutical industry to prove its technical know-how and capitalize on its massive local drug market (which is the second biggest in the world).

AstraZeneca is also gunning for a China-first approval this year for its new anemia treatment, roxadustat, which is being developed as a collaboration with FibroGen.

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments